Full coverage· Health· Updated
Moderna's Melanoma Vaccine Shows Promise, But Stock Falls Amid High Expectations
Moderna and Merck's experimental personalized melanoma vaccine, combined with Keytruda, reduced the risk of recurrence or death by 42% in a Phase 3 trial. Despite the promising results, Moderna's stock fell nearly 18% due to high investor expectations not being fully met.
1 newsroom · 2 languages · since
Plus
What happened
- 01Moderna and Merck's melanoma vaccine plus Keytruda cut recurrence or death risk by 42% in a Phase 3 trial.
- 02Moderna's stock plunged nearly 18% despite positive trial results, driven by unmet Wall Street expectations.
- 03The personalized mRNA vaccine is custom-made for each patient, targeting unique tumor mutations.
- 04The companies aim for a potential U.S. launch in 2027, pending regulatory approval.
- 05Success in melanoma may not translate to other cancers, with further trials ongoing.
- 06Oncologists view the vaccine as a major step forward in personalized cancer treatment.
The companies are targeting a 2027 launch, but regulatory and broader cancer application challenges remain. Oncologists hail the personalized mRNA approach as a significant advancement.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link below.
The coverage
One newsroom on this story
Who covered it
Coverage from Ynetnews More reports may be added as coverage is matched.